Generation Bio to Present at William Blair Biotech Focus Conference
July 08, 2021 07:30 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that...
Generation Bio to Present at the JMP Securities Life Sciences Conference
June 09, 2021 07:30 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that...
Generation Bio to Present at the Jefferies Virtual Healthcare Conference
May 27, 2021 07:30 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that...
Generation Bio Presents Preclinical Data Demonstrating Broad Potential of Gene Therapy Platform at ASGCT and Reports First Quarter Financial Results
May 12, 2021 16:20 ET
|
Generation Bio Co.
Durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model Next-generation rapid enzymatic synthesis of closed-ended DNA further increases...
Generation Bio to Present at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting
April 27, 2021 16:35 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced three...
Generation Bio to Present at 20th Annual Needham Virtual Healthcare Conference
April 08, 2021 07:30 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that...
Generation Bio Reports Fourth Quarter and Full Year 2020 Financial Results
March 18, 2021 08:00 ET
|
Generation Bio Co.
$262.3 million cash balance at the end of 2020 bolstered by additional net proceeds of $211.3 million from follow-on offering, funding key milestones into 2024 Ron Cooper appointed to Board of...
Generation Bio Appoints Ron Cooper to Its Board of Directors
February 18, 2021 07:30 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, announced today that Ron Cooper...
Generation Bio Announces Closing of Public Offering
January 11, 2021 17:43 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the...
Generation Bio Announces Pricing of Public Offering
January 06, 2021 21:24 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of a...